Short answer:
Yes—Cosentyx (secukinumab) is approved for use in children, but only for certain age groups and conditions, and it’s used only under careful medical supervision.
---
What Cosentyx Does
Cosentyx is an IL‑17A inhibitor.
It blocks the inflammatory protein interleukin‑17A, which plays a major role in the skin and joint inflammation seen in:
| Condition | Approved age group (FDA) | Typical dose schedule |
|-----------|--------------------------|-----------------------|
| Plaque psoriasis | 6–12 y (and 12 y‑older) | 150 mg SC every 4 weeks (loading: 4 × 150 mg at weeks 0, 1, 2, 3, then every 4 weeks) |
| Psoriatic arthritis | 12 y and older | 150 mg SC every 4 weeks (same loading) |
| Ankylosing spondylitis | 12 y and older | 150 mg SC every 4 weeks (same loading) |
| (Other indications are adult‑only at this time.) | | |
(Weight‑based dosing is sometimes used for younger children, but the standard 150 mg is the approved adult dose and is used in most pediatric cases.)
---
Why It’s Considered Safe in Children
| Safety data | Key points |
|-------------|------------|
| Clinical trials | Several phase 3 studies enrolled 600+ children 6‑12 y with moderate‑to‑severe plaque psoriasis. 2‑year data show sustained efficacy and a safety profile similar to adults. |
| Common adverse events | Upper‑respiratory infections, nasopharyngitis, headache, mild injection‑site reactions. These are generally mild to moderate. |
| Serious infections | Occur at a low rate (<1 % of patients). Most are upper‑respiratory; severe infections (sepsis, opportunistic infections) are rare. |
| Infections of the gut | Candida (thrush) and mild diarrhea reported; rarely IBD flares. |
| Vaccinations | Live‑attenuated vaccines are not recommended while on Cosentyx. Inactivated vaccines are safe. |
| Long‑term safety | No signals of cancer, serious organ toxicity, or severe autoimmune complications have emerged in the pediatric trials to date. |
Bottom line: In the studied age groups, Cosentyx has a known safety profile that is reassuringly similar to that seen in adults, with no unexpected pediatric‑specific risks.
---
Who Should Not Take It
| Situation | Why it’s a concern |
|-----------|--------------------|
| Active infection (especially severe, systemic, or opportunistic) | Immunosuppression could worsen the infection. |
| Known or suspected inflammatory bowel disease (IBD) | IL‑17A blockade can worsen Crohn’s disease and ulcerative colitis. |
| Recent live‑attenuated vaccine | Risk of vaccine‑related disease. |
| Certain immunocompromising conditions (e.g., HIV, active malignancy) | Limited data; high infection risk. |
| Age < 6 y | Not yet FDA‑approved; insufficient safety data. |
---
How It’s Managed in Practice
1. Baseline evaluation
• Full medical history, physical exam, laboratory work (CBC, CMP, CRP/ESR).
• Screening for latent TB and hepatitis B/C if indicated.
• Discuss vaccination status and schedule.
2. Dosing & Monitoring
• Weight‑based calculations for younger children may be used; otherwise 150 mg SC.
• Monitor for infections, injection‑site reactions, and lab abnormalities every 3–6 months.
3. Follow‑up
• Re‑evaluate disease activity (Psoriasis Area Severity Index, BASDAI, etc.) regularly.
• Adjust dose only if evidence of inadequate response or safety concerns arise.
4. Patient & Caregiver Education
• Teach recognition of infection signs (fever, cough, diarrhea).
• Advise on injection technique, site rotation, and local care.
• Encourage prompt reporting of any new symptoms.
---
Frequently Asked Questions
| Question | Answer |
|----------|--------|
| Can my child have Cosentyx if they’ve had a mild cold? | A mild cold is usually fine, but any serious infection (fever >38.5 °C, persistent cough, etc.) should be evaluated before starting or continuing therapy. |
| Will Cosentyx affect my child’s growth? | No evidence suggests it impairs growth. In fact, effective disease control often improves overall health and activity levels. |
| Can my child take other medications with Cosentyx? | Most systemic drugs are compatible. Avoid concurrent biologics or other immune‑modulating therapies unless directed by the treating physician. |
| What if my child experiences severe side effects? | Stop the drug immediately and contact your pediatric dermatologist/physician. |
| Is it safe during pregnancy? | Cosentyx is category B; data are limited. If a pregnancy is planned or occurs, weigh benefits vs. risks with your provider. |
---
Bottom Line
- Cosentyx is FDA‑approved for children 6–12 y with moderate‑to‑severe plaque psoriasis (and for 12 y and older with psoriatic arthritis or ankylosing spondylitis).
- Safety data are reassuring and comparable to adults, with no unexpected pediatric complications reported.
- Use only under a pediatric dermatologist or rheumatologist’s guidance, with appropriate baseline testing, monitoring, and patient education.
If you’re considering Cosentyx for your child, talk to your child’s physician to review the individual risks, benefits, and monitoring plan.